Cargando…

Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has thrown a challenge to the scientific community. Several interventions to stop or limit the spread of infection have failed, and every time the virus emerges, it becomes more contagious and more deadly. Vaccinating a significant proport...

Descripción completa

Detalles Bibliográficos
Autores principales: Basheeruddin Asdaq, Syed Mohammed, Jomah, Shahamah, Rabbani, Syed Imam, Alamri, Ali Musharraf, Salem Alshammari, Salman Khalaf, Duwaidi, Badr Sami, Alshammari, Majed Sadun, Alamri, Abdulhakeem S., Alsanie, Walaa F., Alhomrani, Majid, Sreeharsha, Nagaraja, Imran, Mohd.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850041/
https://www.ncbi.nlm.nih.gov/pubmed/35186175
http://dx.doi.org/10.1155/2022/6913772
_version_ 1784652525897515008
author Basheeruddin Asdaq, Syed Mohammed
Jomah, Shahamah
Rabbani, Syed Imam
Alamri, Ali Musharraf
Salem Alshammari, Salman Khalaf
Duwaidi, Badr Sami
Alshammari, Majed Sadun
Alamri, Abdulhakeem S.
Alsanie, Walaa F.
Alhomrani, Majid
Sreeharsha, Nagaraja
Imran, Mohd.
author_facet Basheeruddin Asdaq, Syed Mohammed
Jomah, Shahamah
Rabbani, Syed Imam
Alamri, Ali Musharraf
Salem Alshammari, Salman Khalaf
Duwaidi, Badr Sami
Alshammari, Majed Sadun
Alamri, Abdulhakeem S.
Alsanie, Walaa F.
Alhomrani, Majid
Sreeharsha, Nagaraja
Imran, Mohd.
author_sort Basheeruddin Asdaq, Syed Mohammed
collection PubMed
description Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has thrown a challenge to the scientific community. Several interventions to stop or limit the spread of infection have failed, and every time the virus emerges, it becomes more contagious and more deadly. Vaccinating a significant proportion of the population is one of the established methods to achieve herd immunity. More than 100 COVID-19 vaccines have been designed and tested against the virus. The development of a new vaccine takes years of testing, but due to the pandemic, healthcare authorities have given emergency use authorization for a few vaccines. Among them are BioNTech and Moderna vaccines (mRNA based); ChAdOx1, Gam-COVID-Vac, Janssen vaccines (vector-based); CoronaVac, COVAXIN (virus inactivated); and EpiVacCorona vaccine (viral peptide). Mixtures of vaccines are also being tested to evaluate their efficacy against mutant strains of SARS-CoV-2. All these vaccines in clinical trials have shown robust production of neutralizing antibodies sufficient to prevent infection. Some of the vaccinated people reported serious complications. However, no definitive relationship could be established between vaccination administration and the occurrence of these complications. None of the COVID-19 vaccines approved to date have been found to be effective against all of the SARS-CoV-2 variants.
format Online
Article
Text
id pubmed-8850041
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-88500412022-02-17 Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines Basheeruddin Asdaq, Syed Mohammed Jomah, Shahamah Rabbani, Syed Imam Alamri, Ali Musharraf Salem Alshammari, Salman Khalaf Duwaidi, Badr Sami Alshammari, Majed Sadun Alamri, Abdulhakeem S. Alsanie, Walaa F. Alhomrani, Majid Sreeharsha, Nagaraja Imran, Mohd. Can J Infect Dis Med Microbiol Review Article Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has thrown a challenge to the scientific community. Several interventions to stop or limit the spread of infection have failed, and every time the virus emerges, it becomes more contagious and more deadly. Vaccinating a significant proportion of the population is one of the established methods to achieve herd immunity. More than 100 COVID-19 vaccines have been designed and tested against the virus. The development of a new vaccine takes years of testing, but due to the pandemic, healthcare authorities have given emergency use authorization for a few vaccines. Among them are BioNTech and Moderna vaccines (mRNA based); ChAdOx1, Gam-COVID-Vac, Janssen vaccines (vector-based); CoronaVac, COVAXIN (virus inactivated); and EpiVacCorona vaccine (viral peptide). Mixtures of vaccines are also being tested to evaluate their efficacy against mutant strains of SARS-CoV-2. All these vaccines in clinical trials have shown robust production of neutralizing antibodies sufficient to prevent infection. Some of the vaccinated people reported serious complications. However, no definitive relationship could be established between vaccination administration and the occurrence of these complications. None of the COVID-19 vaccines approved to date have been found to be effective against all of the SARS-CoV-2 variants. Hindawi 2022-02-09 /pmc/articles/PMC8850041/ /pubmed/35186175 http://dx.doi.org/10.1155/2022/6913772 Text en Copyright © 2022 Syed Mohammed Basheeruddin Asdaq et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Basheeruddin Asdaq, Syed Mohammed
Jomah, Shahamah
Rabbani, Syed Imam
Alamri, Ali Musharraf
Salem Alshammari, Salman Khalaf
Duwaidi, Badr Sami
Alshammari, Majed Sadun
Alamri, Abdulhakeem S.
Alsanie, Walaa F.
Alhomrani, Majid
Sreeharsha, Nagaraja
Imran, Mohd.
Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines
title Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines
title_full Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines
title_fullStr Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines
title_full_unstemmed Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines
title_short Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines
title_sort insight into the advances in clinical trials of sars-cov-2 vaccines
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850041/
https://www.ncbi.nlm.nih.gov/pubmed/35186175
http://dx.doi.org/10.1155/2022/6913772
work_keys_str_mv AT basheeruddinasdaqsyedmohammed insightintotheadvancesinclinicaltrialsofsarscov2vaccines
AT jomahshahamah insightintotheadvancesinclinicaltrialsofsarscov2vaccines
AT rabbanisyedimam insightintotheadvancesinclinicaltrialsofsarscov2vaccines
AT alamrialimusharraf insightintotheadvancesinclinicaltrialsofsarscov2vaccines
AT salemalshammarisalmankhalaf insightintotheadvancesinclinicaltrialsofsarscov2vaccines
AT duwaidibadrsami insightintotheadvancesinclinicaltrialsofsarscov2vaccines
AT alshammarimajedsadun insightintotheadvancesinclinicaltrialsofsarscov2vaccines
AT alamriabdulhakeems insightintotheadvancesinclinicaltrialsofsarscov2vaccines
AT alsaniewalaaf insightintotheadvancesinclinicaltrialsofsarscov2vaccines
AT alhomranimajid insightintotheadvancesinclinicaltrialsofsarscov2vaccines
AT sreeharshanagaraja insightintotheadvancesinclinicaltrialsofsarscov2vaccines
AT imranmohd insightintotheadvancesinclinicaltrialsofsarscov2vaccines